Disease:
Venous Thrombosis

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
No VIP available CA VA
rs1799963 NC_000011.10:g.46739505G>A, NC_000011.9:g.46761055G>A, NG_008953.1:g.25313G>A, NM_000506.4:c.*97G>A, NM_001311257.1:c.*97G>A, XR_428840.2:n.1828G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2108622 NC_000019.10:g.15879621C>T, NC_000019.9:g.15990431C>T, NG_007971.2:g.23454G>A, NM_001082.4:c.1297G>A, NP_001073.3:p.Val433Met, rs116975254, rs52819608, rs57319528
C > T
SNP
V433M
No VIP available CA No Variant Annotations available
rs28371685 NC_000010.10:g.96740981C>T, NC_000010.11:g.94981224C>T, NG_008385.1:g.47567C>T, NM_000771.3:c.1003C>T, NP_000762.2:p.Arg335Trp, XM_005269575.1:c.1003C>T, XP_005269632.1:p.Arg335Trp, rs60219528
C > T
SNP
R335W
No VIP available CA No Variant Annotations available
rs28371686 NC_000010.10:g.96741058C>G, NC_000010.11:g.94981301C>G, NG_008385.1:g.47644C>G, NM_000771.3:c.1080C>G, NP_000762.2:p.Asp360Glu, XM_005269575.1:c.1080C>G, XP_005269632.1:p.Asp360Glu, rs57527516
C > G
SNP
D360E
No VIP available No Clinical Annotations available VA
rs6025 NC_000001.10:g.169519049T=, NC_000001.10:g.169519049T>C, NC_000001.11:g.169549811C=, NC_000001.11:g.169549811C>T, NG_011806.1:g.41721G=, NG_011806.1:g.41721G>A, NM_000130.4:c.1601G=, NM_000130.4:c.1601G>A, NP_000121.2:p.Arg534=, NP_000121.2:p.Arg534Gln, rs1801711, rs60031897
T > C
SNP
R534Q
No VIP available CA No Variant Annotations available
rs7900194 NC_000010.10:g.96702066G>A, NC_000010.11:g.94942309G>A, NG_008385.1:g.8652G>A, NM_000771.3:c.449G>A, NP_000762.2:p.Arg150His, XM_005269575.1:c.449G>A, XP_005269632.1:p.Arg150His, rs57530584
G > A
SNP
R150H
No VIP available No Clinical Annotations available VA
rs887829 NC_000002.11:g.234668570C>T, NC_000002.12:g.233759924C>T, NG_002601.2:g.175181C>T, NG_033238.1:g.4652C>T, NM_000463.2:c.-364C>T, NM_001072.3:c.862-7110C>T, NM_007120.2:c.868-7110C>T, NM_019075.2:c.856-7110C>T, NM_019076.4:c.856-7110C>T, NM_019077.2:c.856-7110C>T, NM_019078.1:c.868-7110C>T, NM_019093.2:c.868-7110C>T, NM_021027.2:c.856-7110C>T, NM_205862.1:c.61-7110C>T, XR_241238.1:n.924-7110C>T, XR_241239.1:n.-342C>T, XR_241240.1:n.1023-7110C>T, XR_241241.1:n.942-7110C>T, rs12990609, rs34790730, rs36207722, rs386619532, rs61315639
C > T
SNP
No VIP available CA No Variant Annotations available
rs9332131 NC_000010.10:g.96709039delA, NC_000010.11:g.94949282delA, NG_008385.1:g.15625delA, NM_000771.3:c.817delA, NP_000762.2:p.Lys273Argfs, XM_005269575.1:c.817delA, XP_005269632.1:p.Lys273Argfs
A > -
indel
K273R
No VIP available No Clinical Annotations available VA
rs9923231 NC_000016.10:g.31096368C=, NC_000016.10:g.31096368C>T, NC_000016.9:g.31107689C=, NC_000016.9:g.31107689C>T, NG_011564.1:g.3588G=, NG_011564.1:g.3588G>A, NM_001311311.1:c.-1639G=, NM_001311311.1:c.-1639G>A, NM_024006.5:c.-1639G=, NM_024006.5:c.-1639G>A, NM_206824.2:c.-1639G=, NM_206824.2:c.-1639G>A, XM_005255568.1:c.-1639G=, XM_005255568.1:c.-1639G>A, XM_011545943.1:c.-1639G=, XM_011545943.1:c.-1639G>A, XM_011545944.1:c.-1252G=, XM_011545944.1:c.-1252G>A, XM_011545945.1:c.-1252G=, XM_011545945.1:c.-1252G>A, XR_243303.1:n.-990G=, XR_243303.1:n.-990G>A, XR_950848.1:n.-31G=, XR_950848.1:n.-31G>A, rs117572127, rs17878363, rs60511154
C > A
C > G
C > T
SNP
No VIP available CA VA
rs9934438 NC_000016.10:g.31093557G>A, NC_000016.9:g.31104878G>A, NG_011564.1:g.6399C>T, NM_001311311.1:c.174-136C>T, NM_024006.5:c.174-136C>T, NM_206824.2:c.173+1000C>T, XM_005255568.1:c.174-136C>T, XM_011545943.1:c.174-136C>T, XM_011545944.1:c.174-136C>T, XM_011545945.1:c.173+1000C>T, XR_243303.1:n.823-236C>T, XR_950848.1:n.962-136C>T, rs17641219
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names: 
Synonym
Deep Vein Thromboses; Deep Vein Thrombosis; Deep Venous Thromboses; Deep Venous Thrombosis; Deep-Vein Thromboses; Deep-Vein Thrombosis; Deep-Venous Thromboses; Deep-Venous Thrombosis; Phlebothromboses; Phlebothrombosis; Thromboses, Deep Vein; Thromboses, Deep Venous; Thromboses, Deep-Vein; Thromboses, Deep-Venous; Thromboses, Venous; Thrombosis of vein NOS; Thrombosis, Deep Vein; Thrombosis, Deep Venous; Thrombosis, Deep-Vein; Thrombosis, Deep-Venous; Thrombosis, Venous; Vein Thromboses, Deep; Vein Thrombosis, Deep; Venous Thromboses; Venous Thromboses, Deep; Venous Thrombosis, Deep; Venous thrombosis, NOS
PharmGKB Accession Id: PA446969
External Vocabularies

Curated Information ?

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With
No related diseases are available

Publications related to Venous Thrombosis: 71

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. European journal of clinical pharmacology. 2017. Wattanachai Nitsupa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. BMC research notes. 2016. Kudzi William, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei medical journal. 2016. Cho Sun Mi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. Cardiovascular therapeutics. 2015. An Sook Hee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PloS one. 2016. Tong Hoi Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PloS one. 2016. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. European journal of clinical pharmacology. 2015. Chung Jee-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-The Hokusai-VTE phase 3 study. British journal of clinical pharmacology. 2015. Niebecker Ronald, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. The pharmacogenomics journal. 2014. Jeong E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. European journal of clinical pharmacology. 2014. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Verification of pharmacogenetics-based warfarin dosing algorithms in han-chinese patients undertaking mechanic heart valve replacement. PloS one. 2014. Zhao Li, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatric cardiology. 2013. Nguyen Nguyenvu, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thrombosis research. 2013. Skov Jane, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenetics and genomics. 2013. Cavallari Larisa H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin anticoagulant therapy: a southern Italy pharmacogenetics-based dosing model. PloS one. 2013. Mazzaccara Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics. 2012. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Therapeutic drug monitoring. 2012. Lee Kyung-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thrombosis and haemostasis. 2012. Wei Meng, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clinical pharmacology and therapeutics. 2012. Liu Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clinical therapeutics. 2011. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug metabolism and pharmacokinetics. 2011. Kato Yuya, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics. 2011. Mitchell Cathrine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. The pharmacogenomics journal. 2011. Do E J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. Journal of human genetics. 2011. Choi Jung Ran, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation. International journal of clinical pharmacology and therapeutics. 2011. Yang J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. Journal of thrombosis and thrombolysis. 2011. You Joyce H S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients. Pharmacogenetics and genomics. 2011. Shahin Mohamed Hossam A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease. Annals of clinical and laboratory science. 2011. Moon Hee-Won, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. Journal of biomedicine & biotechnology. 2011. Kringen Marianne K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. Journal of thrombosis and haemostasis : JTH. 2010. Lubitz S A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Voora D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Cavallari L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clinical pharmacology and therapeutics. 2010. Pautas E, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. European journal of clinical pharmacology. 2009. Fuchshuber-Moraes Mateus, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenetics and genomics. 2009. Huang Sheng-Wen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenetics and genomics. 2009. Kim Ho-Sook, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood. 2008. Johnson David C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood cells, molecules & diseases. 2009. Limdi N A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenetics and genomics. 2008. Patrignani Paola, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clinical pharmacology and therapeutics. 2008. Michaud V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic determinants of response to warfarin during initial anticoagulation. The New England journal of medicine. 2008. Schwarz Ute I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clinical pharmacology and therapeutics. 2008. Limdi N A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007. Anderson Jeffrey L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007. Millican Eric A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Extended prophylaxis of venous thromboembolism with idraparinux. The New England journal of medicine. 2007. van Gogh Investigators, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Idraparinux versus standard therapy for venous thromboembolic disease. The New England journal of medicine. 2007. van Gogh Investigators, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics. 2007. Nakai Kenji, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clinical pharmacology and therapeutics. 2007. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Personalized medicine. 2007. Limdi Na, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics. 2007. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. Journal of thrombosis and thrombolysis. 2006. Carlquist John F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Multiple gene polymorphisms and warfarin sensitivity. European journal of clinical pharmacology. 2006. Shikata Eriko, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. Journal of medical genetics. 2006. Li T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica. 2006. Martinelli Ida, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thrombosis and haemostasis. 2006. Herman Darja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clinics in geriatric medicine. 2006. Jacobs Laurie G. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. Journal of human genetics. 2006. Mushiroda Taisei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatric cardiology. 2006. Kosaki K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thrombosis and haemostasis. 2005. Geisen Christof, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenetics and genomics. 2005. Tai Guoying, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005. D'Andrea Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The pharmacogenomics journal. 2005. Wadelius M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004. Sidney Stephen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9 genetic polymorphisms and warfarin. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2004. Redman Andrea R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. European heart journal. 2002. Legnani C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relationship of venous thromboembolism and myocardial infarction with the renin-angiotensin system in African-Americans. American journal of hematology. 2002. Hooper W Craig, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994. Vandenbroucke J P, et al. PubMed